Plasmodium Falciparum MalariaPhase 4ACOIINCT03768908
Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005
A Phase 4 study testing Artemether-lumefantrine and Artesunate + Amodiaquine in people with Plasmodium Falciparum Malaria, run by Professor Anders Björkman.
Trial summary
The primary objective of the study was to determine the PCR-APCR up to day 42 in children <60 months of age, weighing ≥5kg with uncomplicated malaria, treated with either artesunate+ amodiaquine (ASAQ) or artemether-lumefantrine (AL; Coartem®). Read more about this study
- Who is it for?
- Ages Up to 60 months
- Conditions the study is for
- Plasmodium Falciparum Malaria
- What is being tested?
- Artemether-lumefantrine and Artesunate + Amodiaquine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 359 participants
- Where
- No sites listed yet
- Study dates
- 5 Jan 2005to 11 Jul 2005
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 60 months
- All sexes
- Child
Who may be able to join
- Weight ≥5kg
- No general danger signs or severe malaria present (see 4.4.2.1 \& 4.4.2.2)
- History of fever within 24 hours OR axillary temperature ≥ 37.5Cº
- No other cause of fever is detectable
- No severe malnutrition
- Patient has parasite counts between 2000-200,000/ul (50-5000/200 white blood cells)
- Guardian/Patient has understood the procedures of the study and is willing to participate
- Patient able to come for stipulated follow up visits and has easy access to the Study Site
Who cannot join
- General Danger Signs and Complications:
- Not able to drink or breastfeed
- Vomiting everything
- Recent history of convulsions
- Lethargic or unconscious
- Unable to sit or stand (as appropriate for age)
Show all 22Show fewer
- History of allergy to test drugs
- History of intake of any drugs other than paracetamol and aspirin within 3 days
- Signs of Severe Malaria:
- Altered consciousness
- Repeated convulsions
- Inability of oral intake
- Severe anaemia (Hb <5gm/dl)
- Difficulty in breathing (pulmonary oedema, Respiratory Distress Syndrome)
- Shock (small pulse, cold extremities)
- Hypoglycaemia
- Haemoglobinuria (dark coloured urine or Coca-Cola urine)
- Kidney failure (little or no urine in a well-hydrated patient)
- Jaundice (yellow colouring of eyes)
- Hyperpyrexia (temperature above 39.5ºC) in combination with other signs
- Hyperparasitaemia (more than 5% red blood cells parasitized or >200,000 parasites/µl)
- Spontaneous bleeding (Disseminated Intravascular Coagulation)
About this study
Official title: A Multicentre Randomised Comparative Clinical Trial of the Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine (Coartem®) for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Zanzibar
The primary objective of the study was to determine the PCR-APCR up to day 42 in children <60 months of age, weighing ≥5kg with uncomplicated malaria, treated with either artesunate+ amodiaquine (ASAQ) or artemether-lumefantrine (AL; Coartem®).
Secondary objectives included: clinical and laboratory assessment of drug tolerability and safety, evaluation of possible correlation between drug bioavailability and clinical outcome, comparison of efficacy data with the pre-implementation "ACO I" study, parasite and fever clearance, gametocyte carriage, and possible selection of mutations related to quinoline resistance.
Read the detailed description
All children in the right age group presenting with clinical signs of malaria at the study site were considered possible study subjects. The guardians of these children were informed about the study orally in Swahili according to the informed consent form. Those who were not willing to participate in the study were treated according to local standard procedure.
On day 0 the patient was tested for parasites using light microscopy on Giemsa stained blood films. A detailed clinical history and a clinical examination including an axillary temperature was assessed. Haemoglobin was assessed and blood samples were collected on filter paper for each child for genotyping of the parasites as well as for possible determination of blood levels of different antimalarial drugs.
The guardian was asked to bring their child back to the study site on day 1, 2, 3, 7, 14, 21, 28, 35 and 42. If they failed to do so they were visited in their homes to assure proper follow-up. At each follow-up the investigator asked about concomitant medication and adverse events, carefully filling out the clinical report form (CRF).
If, during the follow-up between day 14 and 42, a child previously enrolled in the study presented with fever, all tests and examinations were run as on day 0. If the child was clinically and parasitologically diagnosed with malaria again, he was treated as a new infection. If diagnosed with severe malaria during the follow-up period the patient was given rescue treatment (oral or intravenous Quinine) and withdrawn from the study. Each time an enrolled child presented at the site the CRF was completed with regards to clinical and laboratory status, treatment given and possible adverse events.
Clinical and laboratory assessments included:
Malaria smear: Giemsa stained thick blood films examined using electrical or sunlight microscope at the study site by an experienced microscopist. The number of parasites were calculated as the number of parasites seen against 200 leucocytes in the thick blood film and recorded in the CRF for the correct occasion. The slides were stored for quality controls double-check (10% of all slides) centrally.
Haemoglobin: Haemoglobin levels were measured by the HaemoCue™ method using blood samples collected on cuvettes. The Hb levels were recorded in the CRF for each occasion.
Full Blood Picture (FBP) and Liver Function Test (LFT): FBP and LFT were performed in the Kivunge Study Site sub-population only (GLP Sub Study). FBP was obtained using the Cell-Dyn 1700™ Haematology Analyser (Abbott Laboratories, USA). LFT, including ALT, AST, Gamma-GT, albumin and bilirubin, was obtained using the BTS-310™ Photometer UV-VIS (BioSystems, Spain).
Temperature and Clinical history: A medical doctor/officer measured the patient's axillary temperature using an electronic thermometer and took a detailed clinical history as well as performed a clinical examination.
PCR Filter paper sample: Blood samples were collected on Whatman FTA filter papers. When dry, each filter paper sample was stored in separate plastic bags at -20ºC (Kivunge) or +4ºC (Micheweni) until regularly transferred to Kivunge for -20ºC long term storage.
HPLC samples (Kivunge only): Approximately 5ml of venous blood was drawn from each patient on days 0 and 7 for FBP and LFT tests. In the ASAQ group 100 µl of this blood was collected on special filter papers for high pressure liquid chromatography (HPLC) analysis of amodiaquine levels. In the AL group 100 µl of plasma (separated by centrifugation at >3000rpm for 10min) was collected on special filter papers for HPLC analysis of lumefantrine levels. All remaining (minimum 2ml) of plasma was collected and kept at -20ºC as a back-up.
Molecular analyses: PCR genotyping of merozoite surface protein 2 (msp2), considered the most informative single genetic marker for multiplicity of P. falciparum infections, was performed to differentiate reinfections from true recrudescence. Paired PCR results were compared between day 0 and at the time of recurrent parasitaemia from day 14 up to day 42. The outer conserved region of the polymorphic repetitive block 3 of msp2 was amplified in an initial reaction followed by two nested reactions with oligonucleotide primers specific for the two allelic families FC27 and IC/3D7, using a standard protocol. The pfmdr1 Y86N and pfcrt K76T genes' Single Nucleotide Proteins (SNPs) analysis was done according to established AluI restriction-based PCR-RFLP protocols. All molecular analyses were performed at the Malaria Research Unit, KI, Sweden.
- Conditions
- Plasmodium Falciparum Malaria
- Being tested
- Artemether-lumefantrine, Artesunate + Amodiaquine
- Keywords
- Artemether-Lumefantrine, Coartem, Artesunate, Amodiaquine, Zanzibar
- Medical subject headings
- Malaria, Falciparum
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Artemether-lumefantrineDrug
Also called Coartem®
Three day treatment with Artemether-lumefantrine, 2 doses a day under direct observation
Artesunate + AmodiaquineDrug
Also called ASAQ
Three day treatment with Artesunate + Amodiaquine, co-administered, a dose a day under direct observation
| Study group | Role | What they receive |
|---|---|---|
| Treatment with artesunate + amodiaquine | Active comparator | Co-administration of a daily dose of artesunate (Arsumax) 4mg/kg and amodiaquine (Flavoquine) 10mg/kg for 3 days, under direct observation. Children <12months <10kg: artesunate (Arsumax) 50mg - 0.5tab/day + amodiaquine (Flavoquine) 153mg - 0.5tab/day; Children 12-59months 10-20kg: artesunate (Arsumax) 50mg - 1 tab/day + amodiaquine (Flavoquine) 153mg 1 tab/day. Receives: Drug: Artesunate + Amodiaquine |
| Treatment with artemether-lumefantrine (Coartem®) | Active comparator | Artemether-lumefantrine (Coartem®) - artemether 1.3mg/kg + lumefantrine 4mg/kg administered twice daily, both doses under direct observation either in the clinic or in the patient's home. Children <60 months, 5-14kg: 1 tab/dose; Children <60 months >14kg: 2 tabs/dose. Receives: Drug: Artemether-lumefantrine |
What is being measured
The primary outcome is the main question the study is designed to answer.
PCR adjusted parasitological cure rates by day 42
Comparing PCR adjusted parasitological cure rate (PCR-APCR) between the two treatment options up to day 42. Parasitological cure will be adjusted using PCR genotyping of msp2 marker. Recrudescence is defined as the presence of at least one matching allelic band, and reinfection as the absence of any matching allelic band on day 0 and day of recurring parasitaemia. Patients with recurrent parasitaemia having missing filter paper sample or negative PCR results will be considered uncertain with regards to PCR adjusted outcome.
Measured: 42 days
Secondary outcomes (1)
The clinical and parasitological response outcome (i.e. cure rates) on days 14, day 28 and 42.
Comparing proportion of response outcomes according to standard WHO classification i.e., cure rates on days 14, day 28 and 42. Defined as the absence of both re-parasitaemia and clinical symptoms suggestive of severe malaria during follow-up to the respective days.
Measured: 42 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Dec 2018
- Study start5 Jan 2005
- Primary completion11 Jul 2005
- Study completion11 Jul 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Plasmodium Falciparum MalariaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Model description
- A multicentre randomised comparative clinical trial of the efficacy of ASAQ versus AL for the treatment of uncomplicated childhood Plasmodium falciparum malaria.
- Masking
- None (open label)
- Enrolment
- 359 participants (actual)
Sponsor and investigators
- Lead sponsor
- Professor Anders Björkman
- Sponsor type
- University, hospital or other
- Collaborators
- Zanzibar Malaria Control Programme
- Responsible party
- Sponsor-investigator, Professor Anders Björkman, Karolinska Institutet
- Investigators
- Johan Stromberg, Principal investigator, Karolinska InstitutetMwinyi I Msellem, Zanzibar Malaria Control ProgrammeAndreas Martensson, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03768908
- Sponsor's protocol ID
- ACO II
- Acronym
- ACOII
- Status last verified
- Dec 2018
- First submitted
- 3 Dec 2018
- Last updated
- 7 Dec 2018
- Results posted
- No
- Data monitoring committee
- No
Publications
Holmgren G, Hamrin J, Svard J, Martensson A, Gil JP, Bjorkman A. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol. 2007 Sep;7(5):562-9. doi: 10.1016/j.meegid.2007.03.005. Epub 2007 Mar 31.
PubMed 17467344
Study at a glance
From the registry record, last updated by the sponsor on 7 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicentre Randomised Comparative Clinical Trial of the Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine (Coartem®) for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Zanzibar
- ClinicalTrials.gov ID
- NCT03768908
- Acronym / sponsor ID
- ACOII / ACO II
- Conditions
- Plasmodium Falciparum Malaria
- Keywords
- Artemether-Lumefantrine, Coartem, Artesunate, Amodiaquine, Zanzibar
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 359 participants (actual)
- Lead sponsor
- Professor Anders BjörkmanUniversity, hospital or other
- Collaborators
- Zanzibar Malaria Control Programme
- Study start
- 5 Jan 2005 (actual)
- Primary completion
- 11 Jul 2005 (actual)
- Study completion
- 11 Jul 2005 (actual)
- First posted
- 7 Dec 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of the study was to determine the PCR-APCR up to day 42 in children <60 months of age, weighing ≥5kg with uncomplicated malaria, treated with either artesunate+ amodiaquine (ASAQ) or artemether-lumefantrine (AL; Coartem®).
Secondary objectives included: clinical and laboratory assessment of drug tolerability and safety, evaluation of possible correlation between drug bioavailability and clinical outcome, comparison of efficacy data with the pre-implementation "ACO I" study, parasite and fever clearance, gametocyte carriage, and possible selection of mutations related to quinoline resistance.
Detailed description
All children in the right age group presenting with clinical signs of malaria at the study site were considered possible study subjects. The guardians of these children were informed about the study orally in Swahili according to the informed consent form. Those who were not willing to participate in the study were treated according to local standard procedure.
On day 0 the patient was tested for parasites using light microscopy on Giemsa stained blood films. A detailed clinical history and a clinical examination including an axillary temperature was assessed. Haemoglobin was assessed and blood samples were collected on filter paper for each child for genotyping of the parasites as well as for possible determination of blood levels of different antimalarial drugs.
The guardian was asked to bring their child back to the study site on day 1, 2, 3, 7, 14, 21, 28, 35 and 42. If they failed to do so they were visited in their homes to assure proper follow-up. At each follow-up the investigator asked about concomitant medication and adverse events, carefully filling out the clinical report form (CRF).
If, during the follow-up between day 14 and 42, a child previously enrolled in the study presented with fever, all tests and examinations were run as on day 0. If the child was clinically and parasitologically diagnosed with malaria again, he was treated as a new infection. If diagnosed with severe malaria during the follow-up period the patient was given rescue treatment (oral or intravenous Quinine) and withdrawn from the study. Each time an enrolled child presented at the site the CRF was completed with regards to clinical and laboratory status, treatment given and possible adverse events.
Clinical and laboratory assessments included:
Malaria smear: Giemsa stained thick blood films examined using electrical or sunlight microscope at the study site by an experienced microscopist. The number of parasites were calculated as the number of parasites seen against 200 leucocytes in the thick blood film and recorded in the CRF for the correct occasion. The slides were stored for quality controls double-check (10% of all slides) centrally.
Haemoglobin: Haemoglobin levels were measured by the HaemoCue™ method using blood samples collected on cuvettes. The Hb levels were recorded in the CRF for each occasion.
Full Blood Picture (FBP) and Liver Function Test (LFT): FBP and LFT were performed in the Kivunge Study Site sub-population only (GLP Sub Study). FBP was obtained using the Cell-Dyn 1700™ Haematology Analyser (Abbott Laboratories, USA). LFT, including ALT, AST, Gamma-GT, albumin and bilirubin, was obtained using the BTS-310™ Photometer UV-VIS (BioSystems, Spain).
Temperature and Clinical history: A medical doctor/officer measured the patient's axillary temperature using an electronic thermometer and took a detailed clinical history as well as performed a clinical examination.
PCR Filter paper sample: Blood samples were collected on Whatman FTA filter papers. When dry, each filter paper sample was stored in separate plastic bags at -20ºC (Kivunge) or +4ºC (Micheweni) until regularly transferred to Kivunge for -20ºC long term storage.
HPLC samples (Kivunge only): Approximately 5ml of venous blood was drawn from each patient on days 0 and 7 for FBP and LFT tests. In the ASAQ group 100 µl of this blood was collected on special filter papers for high pressure liquid chromatography (HPLC) analysis of amodiaquine levels. In the AL group 100 µl of plasma (separated by centrifugation at >3000rpm for 10min) was collected on special filter papers for HPLC analysis of lumefantrine levels. All remaining (minimum 2ml) of plasma was collected and kept at -20ºC as a back-up.
Molecular analyses: PCR genotyping of merozoite surface protein 2 (msp2), considered the most informative single genetic marker for multiplicity of P. falciparum infections, was performed to differentiate reinfections from true recrudescence. Paired PCR results were compared between day 0 and at the time of recurrent parasitaemia from day 14 up to day 42. The outer conserved region of the polymorphic repetitive block 3 of msp2 was amplified in an initial reaction followed by two nested reactions with oligonucleotide primers specific for the two allelic families FC27 and IC/3D7, using a standard protocol. The pfmdr1 Y86N and pfcrt K76T genes' Single Nucleotide Proteins (SNPs) analysis was done according to established AluI restriction-based PCR-RFLP protocols. All molecular analyses were performed at the Malaria Research Unit, KI, Sweden.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- A multicentre randomised comparative clinical trial of the efficacy of ASAQ versus AL for the treatment of uncomplicated childhood Plasmodium falciparum malaria.
| Arm | Type | Receives |
|---|---|---|
| Treatment with artesunate + amodiaquine | Active comparator | Drug: Artesunate + AmodiaquineCo-administration of a daily dose of artesunate (Arsumax) 4mg/kg and amodiaquine (Flavoquine) 10mg/kg for 3 days, under direct observation. Children <12months <10kg: artesunate (Arsumax) 50mg - 0.5tab/day + amodiaquine (Flavoquine) 153mg - 0.5tab/day; Children 12-59months 10-20kg: artesunate (Arsumax) 50mg - 1 tab/day + amodiaquine (Flavoquine) 153mg 1 tab/day. |
| Treatment with artemether-lumefantrine (Coartem®) | Active comparator | Drug: Artemether-lumefantrineArtemether-lumefantrine (Coartem®) - artemether 1.3mg/kg + lumefantrine 4mg/kg administered twice daily, both doses under direct observation either in the clinic or in the patient's home. Children <60 months, 5-14kg: 1 tab/dose; Children <60 months >14kg: 2 tabs/dose. |
Who may qualify
- Ages
- Up to 60 months
- Sex
- All
- Age groups
- Child
Key inclusion criteria (8 listed)
- Weight ≥5kg
- No general danger signs or severe malaria present (see 4.4.2.1 \& 4.4.2.2)
- History of fever within 24 hours OR axillary temperature ≥ 37.5Cº
- No other cause of fever is detectable
- No severe malnutrition
Key exclusion criteria (22 listed)
- Not able to drink or breastfeed
- Vomiting everything
- Recent history of convulsions
- Lethargic or unconscious
- Unable to sit or stand (as appropriate for age)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Artemether-lumefantrineAlso: Coartem®Three day treatment with Artemether-lumefantrine, 2 doses a day under direct observation | Drug | Treatment with artemether-lumefantrine (Coartem®) |
| Artesunate + AmodiaquineAlso: ASAQThree day treatment with Artesunate + Amodiaquine, co-administered, a dose a day under direct observation | Drug | Treatment with artesunate + amodiaquine |
Primary outcome
PCR adjusted parasitological cure rates by day 42
Time frame: 42 days
Comparing PCR adjusted parasitological cure rate (PCR-APCR) between the two treatment options up to day 42. Parasitological cure will be adjusted using PCR genotyping of msp2 marker. Recrudescence is defined as the presence of at least one matching allelic band, and reinfection as the absence of any matching allelic band on day 0 and day of recurring parasitaemia. Patients with recurrent parasitaemia having missing filter paper sample or negative PCR results will be considered uncertain with regards to PCR adjusted outcome.
1 secondary outcome
The clinical and parasitological response outcome (i.e. cure rates) on days 14, day 28 and 42.
Time frame: 42 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Dec 2018.
- Background: PubMed 17467344Holmgren G, Hamrin J, Svard J, Martensson A, Gil JP, Bjorkman A. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol. 2007 Sep;7(5):562-9. doi: 10.1016/j.meegid.2007.03.005. Epub 2007 Mar 31.
Related trials for Plasmodium Falciparum Malaria
RecruitingPhase 1
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
Malaria Falciparum
Not yet recruiting
Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea
Malaria
Active, not recruitingPhase 4
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics
Malaria,Falciparum, Malaria in Pregnancy
Not yet recruiting
Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee Settings
Malaria (Plasmodium Falciparum), Malaria Incidence
RecruitingPhase 1/2
DON in Pediatric Cerebral Malaria
Malaria, Cerebral
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Johan Stromberg principal investigator
Karolinska Institutet
Mwinyi I Msellem
Zanzibar Malaria Control Programme
Andreas Martensson
Karolinska Institutet
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Artemether-lumefantrine and Artesunate + Amodiaquine in people with Plasmodium Falciparum Malaria, run by Professor Anders Björkman.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PCR adjusted parasitological cure rates by day 42 (time frame: 42 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03768908, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Dec 2018.